Abstract
Objectives: Data on the immune response after two doses of BNT162b2 are so far limited. Previously infected individuals were excluded from pivotal clinical trials and the optimum dose regimen in this population has not been clearly studied. The CRO-VAX HCP study aims to investigate the early antibody response in a population of health-care professionals having received two doses of the BNT162b2 mRNA coronavirus disease 2019 (COVID-19) vaccine.
Methods: The CRO-VAX HCP study is a multicentre, prospective, interventional study conducted in several sites in Belgium. The study included 231 health-care professional volunteers who received the two-dose regimen of the BNT162b2 mRNA COVID-19 vaccine. Of these, 73 were previously infected by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and 158 were uninfected and seronegative. In the first group, blood samples were collected at baseline and after 2, 4, 7, 10, 14, 21 and 28 days. In the second group, samples were obtained at baseline and after 14 and 28 days. Antibodies against the SARS-CoV-2 nucleocapsid and the receptor binding domain of the S1 subunit of the spike protein were measured in all individuals at different time-points.
Results: In uninfected individuals, 95.5% (95% CI 91.0%-98.2%) developed anti-spike antibodies after 14 days and a 24.9-fold rise (95% CI 21.4%-28.9%) in antibody titre was observed after the second dose. In previously infected individuals, peak antibody response was reached after 7 days (i.e. 6347 U/mL) and the second dose did not lead to significantly higher antibody titres (i.e. 8856-11 911 U/mL). Antibody titres were higher in previously infected individuals.
Conclusions: This study supports the concept that a single dose of BNT162b2 would be sufficient in previously infected individuals.
Keywords: Antibody; BNT162b2; Coronavirus disease 2019; Humoral response; Severe acute respiratory syndrome coronavirus 2; Vaccine.
【저자키워드】 severe acute respiratory syndrome coronavirus 2, Coronavirus disease 2019, antibody, vaccine., BNT162b2, Humoral response, 【초록키워드】 COVID-19, coronavirus disease, severe acute respiratory syndrome coronavirus 2, SARS-CoV-2, Coronavirus disease 2019, Vaccine, coronavirus, COVID-19 vaccine, immune response, clinical trial, antibody, Antibody Response, severe acute respiratory syndrome Coronavirus, Spike protein, Receptor binding domain, BNT162b2, Humoral response, nucleocapsid, multicentre, respiratory, Belgium, disease, seronegative, anti-spike antibodies, BNT162b2 mRNA COVID-19 vaccine, BNT162b2 mRNA, single dose, anti-spike antibody, Antibody titre, S1 subunit, dose, lead, Support, acute respiratory syndrome, optimum dose, 95% CI, acute respiratory syndrome coronavirus, acute respiratory syndrome coronavirus 2, antibody titres, Blood samples, second dose, infected individual, infected individuals, individual, blood sample, titre, professional, SARS-CoV-2 nucleocapsid, two-dose regimen, uninfected, Volunteer, hcp, health-care, the S1 subunit, collected, conducted, the spike protein, significantly higher, reached, individuals, were measured, baseline, dose regimen, of BNT162b2, the SARS-CoV-2, were excluded, 【제목키워드】 SARS-CoV-2, mRNA vaccine, Antibody Response, dose, professional, health-care,